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Abstract
Background: In vivo overexpression of proteins is a powerful approach to study their biological function, generate
disease models or evaluate gene therapy approaches. In order to investigate an exogenously expressed protein,
specific and sensitive detection is essential. Unfortunately, antibodies that allow histological detection of the
protein of interest are not always readily available. The use of an epitope tag fused to the protein can circumvent
this problem as well as provide the possibility to discriminate endogenous from overexpressed proteins. In order to
minimize impact on the bioactivity and biodistribution of the overexpressed protein, preference is given to small
tags.
Results: In the present study, we evaluated several small epitope tags together with corresponding anti-tag
antibodies for the detection of overexpressed proteins in rat brain, using eGFP as a reference. We generated
several lentiviral vectors encoding eGFP with different N-terminally fused small epitope tags (AU1, flag, 3flag, HA,
myc and V5). After confirmation of their functionality in cell culture, we injected these lentiviral vectors
stereotactically into the striatum of rats and prepared paraformaldehyde fixed floating sections for
immunohistochemical analysis. Using multiple antibodies and antibody dilutions per epitope tag, we extensively
assessed the efficiency of several anti-tag antibodies for chromogenic immunohistochemical detection of the
epitope tagged eGFPs by determining the proportion of immunoreactivity detected by anti-tag antibodies
compared to anti-GFP antibody. Using fluorescence immunohistochemistry and confocal microscopy, we also
quantified the proportion of eGFP-positive cells detected by anti-tag antibodies. Our results show that all the
examined small epitope tags could be detected by anti-tag antibodies both in cell extracts as well as in vivo,
although to varying degrees depending on the tag and antibody used. Using the presented protocol, V5/anti-V5
and HA/HA11 tag/antibody combinations provided the most sensitive detection in brain tissue. We confirmed the
applicability of these optimized in vivo tag detection conditions for a difficult to detect protein, firefly luciferase
(fLuc), using lentiviral vector constructs expressing V5 tagged and 3flag tagged fLuc protein.
Conclusions: We show here that several small epitope tags are useful for immunohistochemical detection of
exogenous proteins in vivo. Our study also provides a generic methodology which is broadly applicable for the
detection of overexpressed transgenes in mammalian brain tissue.
Background
Since the advent of recombinant DNA technology,
transgenic model organisms have become powerful tools
for the study of the basic biology of proteins or to gen-
erate in vivo models for diseases [1]. The expression of
transgenes in complex organisms is accompanied by the
need for a specific and sensitive detection of the protein.
One approach is the use of a protein specific antibody.
However, antibodies raised against a protein of interest
are not always available, are costly and time-consuming
to produce and are usually not transgene specific. More-
over antibodies are often not suitable for several applica-
tions and immunohistochemical detection is a frequent
bottleneck. These drawbacks can be overcome by the
use of epitope tagging. The fusion of an immunoreactive
epitope tag to a protein provides the possibility to detect
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manner with well-characterized commercially available
antibodies. Moreover, it allows discriminating endogen-
ous from overexpressed proteins.
The performance of an epitope tag in a detection
experiment is dependent not only on the epitope used
but also on the anti-epitope antibody [2]. The selection
of the optimal tag/antibody combination is complicated
and depends on the target protein and the application.
The large variety of combinations allows selecting the
appropriate tag/anti-tag antibody for a particular appli-
cation; however this optimization may be a time-con-
suming process. Despite the extensive documentation
on the use of epitope tagging for in vitro or cellular
applications, very little information is available concern-
ing the use of epitope tags for in vivo applications [2].
In the comparative study presented here, we aimed to
characterize different commonly used small epitope tag/
antibody combinations in cell culture as well as in vivo.
In the selection of different tags, preference was given
to those tags with broad versatility: AU1 [3], HA [4,5],
myc [6], V5 [7], flag and 3flag [8]. In order to evaluate
the different tag/antibody combinations, epitope tags
were N-terminally fused to eGFP and overexpressed by
means of locoregional lentiviral vector-mediated gene
transfer [9]. We evaluated detection of the epitope tags
in cell extracts as well as in the rat striatum in compari-
son to detection of eGFP. As proof-of-principle, we eval-
uated the indirect detection of fLuc protein fused to a
V5 or 3flag tag after locoregional overexpression in the
mouse striatum.
Results
Evaluation of epitope tag expression in cell extracts
HEK293T cells were transduced with lentiviral vectors
encoding different tag-eGFP fusion proteins or eGFP
alone (Table 1 and Fig. 1A). The amount of vector was
normalized for expression based on functional titers
(transducing units; TUs) as described in materials and
methods. Western blot analysis confirmed a clear
expression and detection of all different fusion proteins
and eGFP to comparable levels. Our in-house anti-eGFP
antibody [9] as well as the different commercially avail-
able antibodies detected the appropriate fusion protein
with high specificity. As shown in Fig. 1, no notable pro-
teolytic cleavage of the fusionproteins was observed. In
order to avoid saturation of the western blot signal, the
anti-V5 antibody had to be used at a 1:250000 dilution,
indicating a very sensitive detection of V5-eGFP by this
antibody. To obtain bands with comparable intensity for
cell lysates overexpressing 3flag-eGFP and flag-eGFP;
the former had to be diluted 500 times, showing
increased detection efficiency of the 3flag tag compared
to flag alone.
Evaluation of epitope tag/antibody combinations in vivo
Using the same lentiviral vectors, stereotactic injections
in striatum of adult rats were performed. The use of
tag-eGFP fusion proteins allowed us to use eGFP detec-
tion levels as internal control. Animals were sacrificed 2
weeks post-injection, a time point at which expression
levels reach a maximum [10]. Adjacent sections were
subjected to DAB-based immunohistochemical staining
with our in-house anti-eGFP antibody or the different
tag-specific antibodies. Dilutions were optimized as
described in materials and methods to obtain the opti-
mal signal-to-noise ratio (Table 2).
Comparison of the transduced regions revealed that all
antibodies can detect the corresponding tag-eGFP fusion
protein to varying degrees, although the maximum
detection levels reached by the evaluated anti-tag anti-
bodies were in all conditions lower than the correspond-
ing eGFP detection with our in-house anti-eGFP
antibody (Fig. 2). In order to evaluate the sensitivity of
the different tag/antibody combinations, we determined
the ratio of tag immunopositive surface to eGFP immu-
nopositive surface through the transduced region (Fig.
3). This quantification demonstrates that the V5/anti-V5
and HA/HA11 combinations show the highest sensitiv-
ity. The polyclonal anti-myc antibody on the other hand
detects its antigen, under the conditions tested, with
very low sensitivity.
Next, fluorescent immunohistochemical stainings were
performed to further characterize detection sensitivity as
well as to evaluate specificity at the cellular level (Fig.
4A). Panels with eGFP show primary eGFP fluorescence
without additional staining, detection with the tag-speci-
fic antibodies was performed as described in materials
and methods. This data confirms that all antibodies can
detect the corresponding tag in vivo. Quantification of
the percentage of eGFP-positive cells that stained posi-
tive using the corresponding anti-tag antibody were per-
formed within the centre of the transduced region (Fig.
4B). In this area, where transgene expression levels are
high, all but one of the evaluated tag specific antibodies
detected the corresponding protein with a similar sensi-
tivity between 70 - 90%. The polyclonal anti-myc anti-
body could only detect 10% of the eGFP-positive cells.
Aspecific detection, i.e. presence of tag immunoreactiv-
ity that was not eGFP positive, was negligible in all
cases.
Detection of firefly luciferase using epitope tagging
As proof of principle, we tested immunohistochemical
detection of tagged firefly luciferase (fLuc) following
locoregional overexpression in mouse striatum. Lucifer-
ase, frequently used as in vivo imaging reporter gene,
can generate photons in the presence of its substrate D-
luciferin and ATP. These photons can be detected by a
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confirmation of luciferase expression is often crucial.
Although anti-luciferase antibodies are commercially
available, their sensitivity for immunohistochemical
detection in brain is very low [11]. As the V5 tag/anti-
V5 antibody showed the highest sensitivity for V5-eGFP
in vivo, we tested the detection of V5-tagged luciferase.
As a control for transduced cells, V5-luciferase was co-
expressed with eGFP using a T2A peptide sequence
[12]. The western blot presented in Fig. 5A confirms
expression of our construct. The V5-luciferase fusion
protein could be detected with both the luciferase anti-
body and the anti-V5 antibody in cellular extracts. To
evaluate the detection of V5-luciferase in vivo,w e
injected the lentiviral vector encoding V5-luciferase-
T2A-eGFP in the striatum of mice. To assess the
expression, functionality and stability of luciferase pro-
tein after lentiviral transduction, mice were imaged by
bioluminescence imaging (BLI) at 4 days and 2 weeks
post-injection (1.28E+06 +/- 8.30E+05 and 6.29E+05 +/-
2.65E05) (Fig. 5B). Images of both time points demon-
strated a signal originating from the injected side of the
brain. Animals were sacrificed 2 weeks post-injection
and brains were processed for immunohistochemical
analysis. In order to evaluate detection efficiency, adja-
cent sections were incubated with either the anti-V5
antibody, anti-luciferase antibody or the in-house anti-
eGFP antibody (Fig. 5C). Despite confirmation of luci-
ferase activity by BLI, the anti-luciferase antibody failed
to detect the transgene, while the anti-V5 antibody
clearly detected V5-luciferase in the transduced region
visualized by eGFP.
Discussion
Exogenous gene transfer into the brain is an important
strategy to study in vivo protein function, investigate
pathogenic mechanisms of diseases as well as develop
new therapeutic strategies. However, the study of exo-
genously expressed proteinsr e q u i r e sr i g o r o u sa s s e s s -
ment of transgene expression, preferentially distinct
from the corresponding endogenous protein. In this
study, we have used lentiviral vector-based expression of
Figure 1 SDS-PAGE analysis of tag-eGFP fusion proteins in LV transduced HEK293T cells. A) Schematic representation of the tag-eGFP
constructs. Peptide sequences are listed in table 1. B) Overexpressed proteins were detected with an in-house anti-eGFP antibody. C) The same
lysates as in B) were analyzed with the different anti-tag antibodies. 2 μg of cell lysate was loaded and antibody dilutions were as follows: anti-
eGFP (1/10000), anti-AU-1 (1/25000), anti-V5 (1/250000), 9E10 (1/10000), FlagM2 (1/30000) and HA 11 (1/50000). b-tubulin was used as loading
control. * cell lysate of 3flag-eGFP was loaded at 4 ng to avoid saturation of the western blot signal.
Table 1 Overview of evaluated small epitope tags
Tag Sequence
Triple flag DYKDHDGDYKDHDIDYKDDDDK
flag DYKDDDDK
V5 GKPIPNPLLGLDST
myc EQKLISEEDL
HA YPYDVPDYA
AU1 DTYRYI
Peptide sequences of evaluated small epitope tags. All tags were N-terminally
fused to an eGFP sequence in which the start codon had been replaced, a
RDPPVAT sequence was used as linker. Untagged eGFP was included as
control.
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terminally fused to eGFP in rat brain to evaluate immu-
nohistochemical detection of several commonly used
epitope tags in floating sections. In this way, we have
evaluated the performance of several commonly used
epitope tag/antibody combinations.
First, we evaluated the detection of the different epi-
tope tags in HEK293T cell extracts after transduction
with lentiviral vectors encoding the different tag-eGFP
fusion proteins. Western blot analysis shows a distinct
and specific detection using our in-house anti-eGFP
antibody as well as all examined anti-tag antibodies.
Especially the V5/anti-V5 antibody and 3flag/FlagM2
antibody combinations allow a very sensitive detection
in cell extracts (Fig. 1C).
The main goal of this study was to compare in vivo
detection of different frequently used epitope tags using
commercially available antibodies. Chromogenic DAB-
based as well as fluorescent immunohistochemical
detection of the overexpressed tags revealed that all epi-
tope tag/antibody combinations, with the exception of
myc/polyclonal anti-myc, meet the requirements of a
specific and sensitive detection in rat brain (Fig. 2, 3
and 4). The specificity of the V5/anti-V5 and HA/HA11
combinations are comparable with the other combina-
tions; however the sensitivity seems to be higher since
lower antibody concentrations were used for optimal
immunohistochemical detection (Fig. 3 and Table 2).
These differences were most apparent for the immuno-
histochemical detection with DAB. The polyclonal anti-
myc antibody on the other hand, detects its antigen
with low sensitivity as well as low specificity. Therefore,
using the presented protocol, our findings show that all
tag/antibody combinations, with the exception of myc/
polyclonal anti-myc, show sufficient sensitivity and spe-
cificity for immunohistochemical analysis in brain tissue.
Based on the strong increase in sensitivity in western
blotting detection, we expected the detection of the
3flag tag in vivo to be more sensitive compared to the
flag tag; however no significant differences in sensitivity
were observed between these two tags using either the
monoclonal FlagM2 antibody or a polyclonal anti-flag
antibody.
In terms of sensitivity, our in-house eGFP antibody
was superior to all tested tag antibodies. However by
using a large protein such as eGFP itself as tag for a
protein of interest, caution should be exercised since
eGFP fusion might interfere with the normal protein
function, especially for small proteins. An alternative
strategy could consist of a bicistronic construct using a
T2A-like peptide [12], although a minor fraction of
fusion protein might be produced with this system.
As proof-of-principle experiment, we overexpressed
firefly luciferase tagged with V5 and co-expressed with
eGFP in mouse striatum. Luciferase activity was con-
firmed via bioluminescence imaging. The enzymatic
activity of fLuc was not affected by tagging with V5
since the BLI signal per injected transducing unit vector
d o e sn o td i f f e rf r o mu n t a g g e df L u c( 3 , 3p / s / T Uf o rV 5 -
fLuc versus 2,3 p/s/TU for untagged fLuc). However,
immunohistochemical analysis using a commercial anti-
luciferase antibody failed to detect the transgene. In
Table 2 Detailed overview of characterized antibodies
Epitope Antibody Clonality Company Product
N°
Concentration Optimal dilution for IHC
based on current study
Optimal concentration (μg/ml) for
IHC based on current study
3flag
and flag
Anti-flag
polyclonal
1
Polyclonal Sigma F7425 0.8 mg/ml 1/5000 0.16
FlagM2
1 Monoclonal Sigma F3165 5 mg/ml 1/12500 0.4
V5 Anti-V5
3 Monoclonal Invitrogen R960-25 1.07 mg/ml 1/12500 0.0856
Myc Anti-Myc
2
Polyclonal
Polyclonal Upstate 06-549 1 mg/ml 1/5000 0.2
9E10
3 Monoclonal Santa Cruz Sc-40 0.2 mg/ml 1/1000 0.2
HA HA 11
3 Monoclonal Covance MMS-
101R
2-3 mg/ml 1/25000 0.1
12CA5
3 Monoclonal Roch
Applied
11 583
816 001
0.4 mg/ml 1/5000 0.08
AU1 Anti-AU1
3 Monoclonal Covance MMS-
130R
5-7 mg/ml 1/5000 1.2
GFP Anti-eGFP
4
Polyclonal
Polyclonal In-house - - 1/10000 -
1 affinity purified IgGs using a column bearing the inmmunizing peptide
2 affinity purified IgGs using a column bearing protein A
3 purification method not specified
4 not purified
In order to compare antibody dilutions, the optimal dilutions (based on current study) for IHC reckoned with the antibody concentration are mentionedi nt h i s
table.
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using the V5 antibody (Fig. 5). The detection sensitivity
with the V5 antibody appears somewhat lower than in
the case of the V5-eGFP fusion protein (Fig. 2). This
may be attributed to differences in stability of the two
proteins (eGFPT1/2: >10 h, fLucT1/2: 3 h) since initial
protein levels of V5-luciferase and eGFP are identical
when co-expressed using a T2A sequence [12]. This
example clearly underlines the advantage of epitope
tagging for sensitive and specific detection of an exogen-
ous protein which is otherwise not readily detectable
with IHC.
In order to confirm the previous data with another
tag, 3flag-luciferase-T2A-eGFP was injected and BLI sig-
nals were measured. We could confirm that the activity
of tagged fLuc is maintained and even slightly increased
(157,20 p/s/TU for 3flag-fLuc versus 38,84 p/s/TU for
untagged fLuc). We therefore conclude that tagging of
luciferase with either a V5 or 3flag tag does not
adversely affect sensitivity of bioluminescence imaging
in the brain.
One of the main concerns fusing a small epitope tag
to a protein of interest is the potential impact on prop-
erties such as biodistribution, stability, enzymatic activity
and binding capacity. Since such effects cannot be pre-
dicted, control studies comparing the tagged protein
with the wild-type counterpart should always be
included [13-15]. However, interference with the tertiary
structure and bioactivity can be minimized by using
short peptide sequences fused to the terminus of the
protein [16].
Besides immunohistochemical detection evaluated in
the present study, fusing a small peptide to any gene of
interest also offers great benefit in several other applica-
tions. For instance, epitope tags can be used as an affi-
nity tag to perform proteinp u r i f i c a t i o nw h e nu s i n g
stringent purification conditions or to identify interact-
ing proteins when combining non-stringent affinity puri-
fications and mass spectrometry analysis of co-purified
proteins [16-27]. Moreover, modifications of the small
peptide sequence may further enlarge the range of appli-
cations [28]. An interesting new development is for
example the generation of a drug-controllable tag [29].
It should be noted that sinc et h ec h o i c eo ft a g / a n t i -
body combinations is endless and the ideal epitope tag
may vary for every transgene and every application,
there is still a need for optimization and characterization
studies when tagging a new protein [17,30]. The evalua-
tion of several commonly used tag/antibody combina-
tions in vivo presented here can be used as an aid in the
selection of tags to assess in priority. Moreover, we offer
a straightforward protocol for immunohistochemical
analysis of tagged exogenous protein expressed in
rodent brain which can be readily applied for any new
protein of interest.
Conclusions
In conclusion, the present study provides an extensive
overview of small epitope tags and corresponding antibo-
dies for immunohistochemical detection of transgenes in
vivo. Using the presented protocol, V5/anti-V5 and HA/
HA11 are the preferable tag/antibody combinations for
immunohistochemical analysis in brain tissue while
Figure 2 In vivo detection of tag-eGFP constructs.R a t sw e r e
stereotactically injected in the striatum with lentiviral vectors
encoding the tag-eGFP fusion protein. The overexpressed protein
(indicated on the left) was detected in adjacent sections with either
the anti-eGFP antibody or the anti-tag antibody as indicated.
Antibody dilutions used are given in table 2. Scale bar: 1 mm.
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antibody is not an ideal candidate. Our study yields a
straightforward protocol for sample preparation and
immunohistochemical staining in floating sections of brain
tissue. We show in this study that tagging a protein with a
small epitope tag is a powerful approach to obtain sensi-
tive and specific detection of overexpressed proteins while
reducing the risks of altering the transgene’sf u n c t i o n .
Methods
Cloning
The different epitope tags AU-1 (6 amino acids (aa)),
flag (8 aa), 3flag (22 aa), HA (9 aa), myc (10 aa) and V5
(14 aa) were N-terminally fused to eGFP (Tables 1 and
2 and Fig. 1A) by adaptor ligation in a peGFP-N1 plas-
mid (Clontech, Mountain View, CA, USA). All tagged
eGFP constructs contained a linker sequence between
tag and eGFP of RDPPVAT. To avoid eGFP expression
alone, we mutated the startcodon of eGFP to ATT via a
PCR based method [31]. These fusion DNA sequences,
as well as eGFP alone, were subcloned into the
pCHMWS plasmid backbone, an in-house lentiviral
transfer plasmid (as described in [10]) in which trans-
gene expression is under control of a CMV promoter.
V5-fLuc and 3flag-fLuc, followed by a T2A eGFP
sequence, were also cloned into the pCHMWS back-
bone. The T2A sequence allows bicistronic gene expres-
sion since the presence of this viral peptide results in
equimolar expression of V5-fLuc or 3flag-fLuc and
eGFP [12]. All constructs were sequence confirmed.
Lentiviral vector production
HIV-1-derived vector particles encoding the fusion pro-
teins tag-eGFP, V5-luciferase-T2A-eGFP, 3flag-lucifer-
ase-T2A-eGFP or eGFP alone were produced, essentially
as described in Ibrahimi et al. [12]. Briefly, after seeding
HEK293T cells in a 10-cm dish, we performed a triple
transient transfection with the respective transfer plas-
mids, a packaging plasmid and an envelope plasmid
encoding VSV G. The production was performed in
Opti-MEM I (Gibco-Invitrogen, Merelbeke, Belgium).
The medium was replaced after 24 h. Cell supernatant
containing lentiviral vectors was collected on day 2 and
3 post-transfection, filtered through a 0.45 μm pore size
filter (Sartorius, Minisart, Göttingen, Germany) and con-
centrated 50-fold using a Vivaspin 15 column
(Vivascience, Hannover, Germany).
Functional vector titers were determined by transdu-
cing HEK293T cells with the respective vector prepara-
tions in a 10-fold dilution series. Three days after
transduction, cells were harvested and fixed in 4% paraf-
ormaldehyde (PAF) and analysed using a FACSCalibur
flow cytometer (BD Biosciences, Erembodegem, Flan-
ders) and the CellQuest software package provided with
the instrument. These functional vector titers are
expressed as transducing units (TUs) per ml.
Antibodies
Table 2 shows an overview of the antibodies used in the
present study. These antibodies were used for detection
via western blotting as well as IHC. To determine the
optimal antibody dilution for immunohistochemical eva-
luation, three different dilutions were tested: the anti-
body manufacturer’s recommended dilution as well as a
5-fold lower and 5-fold higher dilution. Depending on
t h eo r i g i no ft h ep r i m a r ya n t ibody, goat-anti-mouse or
goat-anti-rabbit secondary antibodies were used.
Cell culture and transduction
HEK293T cells were maintained in Dulbecco’sm o d i f i e d
Eagle’s medium (Gibco) supplemented with 10% heat-
inactivated fetal calf serum (Harlan Sera-Lab Ltd., Inter-
national Medical, Brussels, Belgium) and 50 μg/ml gen-
tamycin at 37°C in a humidified atmosphere containing
5% CO2.
Cells were seeded in a 24 well plate at 200000 cells/
well. 24 h after seeding, cells were transduced using 10
6
TUs/ml vector. After 48 h, cells were harvested and
lysed in 1% sodium dodecyl sulphate (SDS) lysis buffer
containing protease inhibitor cocktail (Sigma-Aldrich,
Bornem, Belgium).
Western blot analysis
Protein content of cell lysates was determined using the
bicinchoninic acid (BCA) protein determination assay
Figure 3 Quantification of detection of tag-eGFP constructs.
Proportion of the transduced surface detected by the anti-tag
antibody compared to the surface detected by the anti-eGFP
antibody on adjacent slides. Three slides through the transduced
region were quantified per animal with n = 3 per condition. Results
are expressed as mean percentages +/- the standard error of the
mean.
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Page 6 of 10Figure 4 Detailed immunofluorescent detection of overexpressed tag-eGFP in vivo. Adjacent sections of the analyzed tissue described in
Fig. 2 and 3 were immunofluorescently stained with anti-tag antibody using the dilutions given in table 2. A) A representative picture is shown
for each tag/antibody combination, the left part shows eGFP fluorescence, the middle part shows the tag staining and the right part is a
merged picture of the two individual pictures. Overlay pictures reveal the degree of anti-tag antibody sensitivity. Scale bar: 50 μm. B) Mean
percentage transduced cells recognized by the specific anti-tag antibody for each tag. Twelve images per animal (n = 3) were counted per
epitope tag. Results are expressed as means with standard error of the mean.
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were boiled in 1% SDS sample buffer containing pro-
tease inhibitor cocktail for 5 minutes (min). 2 μgo f
each total protein extract was resolved on a 12.5% poly-
acrylamide gel. Separated proteins were transferred to a
polyvinylidene fluoride membrane and aspecific binding
sites were blocked for 30 min in PBS supplemented
with 0.1% Triton X-100 (PBST) and 5% non-fat milk.
After overnight incubation at 4°C with the appropriate
antibody, blots were washed 3 times with PBST. An
anti-mouse beta-tubulin antibody was used as loading
control. After incubation with the appropriate horserad-
ish peroxidase-labeled secondary antibody, blots were
again washed as mentioned before. Bands were visua-
lized using enhanced chemiluminescence (Amersham
Pharmacia Biotech, Little Chalfont, England).
Stereotactic injections and perfusion
Housing and handling of rats and mice were done in
compliance with national guidelines; all animal proce-
dures used were approved by the Institutional Care and
Use Committee of the Katholieke Universiteit Leuven.
All experiments involving viral vectors were carried out
under biosafety level 2 conditions.
Eight week old female Wistar rats were used for tag-
eGFP injections, while eight week old female C57BL/6-
Tyrc-2J/J mice were used for BLI. The animals were
anaesthetized and placed in a stereotactic head frame.
After making a midline incision of the scalp, a burr
hole was drilled in the appropriate location at both
sites of the skull using bregma as reference. Following
coordinates were used for mouse and rat respectively:
anteroposterior 0.5 and 0 mm; lateral 2.0 and 2.8 mm;
dorsoventral 3.0 and 5.5 mm. Three microliters (corre-
sponding to 1.26 E+04 to 5.67 E+04 TU) of lentiviral
vector supplemented with polybrene (to 4 μg/ml) was
injected in rat striatum at a rate of 0.25 ml/min with a
30-gauge needle on a 10-ml Hamilton syringe. Mice
were injected with 2 microliters lentiviral vector. After
the injection, the needle was left in place for an addi-
tional 5 min before being slowly withdrawn from the
brain (adapted from [32]). Two weeks later, animals
were deeply anesthetized using an overdose of pento-
barbital and transcardially perfused with saline
Figure 5 Detection of V5-fLuc after intrastriatal LV injection in mice. As proof of principle experiment, V5 was fused to fLuc in order to
facilitate the transgene detection. A) HEK293T cell lysates transduced with LV encoding V5-fLuc-T2A-eGFP were analyzed by SDS-PAGE. The
overexpressed fusion protein was detected with both the anti-fLuc antibody (1/3000) and the anti-V5 antibody (1/250000). The co-expressed
eGFP was detected by our in-house anti-eGFP antibody (1/10000). B) The same LV as in A) was stereotactically injected in mice striatum.
Luciferase activity was confirmed by non-invasive BLI four days and two weeks after injection. A representative image of luciferase activity 4 days
post-injection is shown. C) Striatal sections of the same mice as described in B) were immunohistochemically stained with anti-eGFP (1/10000),
anti-V5 (1/500) and anti-fLuc antibody (1/500). Scale bar: 0.5 mm.
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Page 8 of 10followed by ice-cold 4% PAF in PBS. The brain was
r e m o v e df r o mt h es k u l la n dp o s t - f i x e do v e r n i g h ti n4 %
PAF-PBS at 4°C.
Histology
50-mm-thick coronal brain sections were cut with a
microtome (HM650V, Microm, Walldorf, Germany)
and stored at 4°C in PBS with 0.1% sodium azide. The
transduced area was identified based on eGFP expres-
sion using an inverted fluorescence microscope (Leica
DMR optical microscope, Microsystems, Wetzlar, Ger-
many). Sections around this injection area were used
for histology with the different tag/antibody
combinations.
Polyclonal in-house rabbit anti-eGFP antibody [9], a
small epitope anti-tag antibody (Table 2) or anti-lucifer-
ase antibody (Promega, Madison, WI, USA) was used to
detect the transgene. Chromogenic immunostaining was
performed using an avidine-biotine-peroxidase complex
immunostaining technique and carried out under uni-
form conditions. To remove endogenous peroxidase
activity, sections were incubated with 3% hydrogen per-
oxide in PBS for 10 min. Non-specific sites were
blocked by pre-treatment with 10% normal goat serum
in PBST. Sections were then incubated overnight at
room temperature with the appropriate primary anti-
body diluted in PBST with 10% goat serum as described
in table 2. After being washed 3 times 5 min with PBST,
the sections were incubated for 30 min at room tem-
perature with goat anti-rabbit or anti-mouse biotinylated
secondary antibody (Dako, Glostrup, Denmark) diluted
at 1:300 in PBST. The sections were washed in PBST 3
times 5 min and incubated with Strept-ABC-HRP com-
plex (Dako) for 30 min. After another wash step, detec-
tion was performed with diaminobenzidine (DAB) with
H2O2 as substrate. The sections were coverslipped on
gelatin-coated slides with DPX (Fluka, Bornem,
Belgium).
For fluorescent staining, sections were incubated over-
night with the appropriate primary antibodies diluted in
PBST, 10% sodium azide and 10% goat serum. After
three PBST rinses, sections were incubated for 2 hours
at room temperature with goat anti-rabbit or goat anti-
mouse IgG-Alexa 633 (diluted 1: 500, Invitrogen Mole-
cular Probes). Sections were again rinsed with PBST and
mounted on microscope slides with polyvinyl alcohol
(Mowiol; Merck, La Jolla, CA, USA).
Sensitivity and specificity of the staining were quanti-
fied as described below under ‘microscopy analysis’.
In vivo bioluminescence imaging
BLI of fLuc activity was performed as described in
D e r o o s ee ta l .[ 1 1 ] .S h o r t l y ,m i c ew e r ei m a g e di na n
IVIS 100 system (Xenogen, Alameda, CA, USA).
Anaesthesia was induced in an induction chamber with
2.5% isoflurane in 100% oxygen and maintained in the
IVIS imaging chamber. The mice were injected intrave-
nously with D-luciferin (126 mg/kg, Xenogen) dis-
solved in PBS (15 mg/ml). Subsequently, they were
placed in the prone position in the IVIS and 1 min
frames were acquired until the maximum signal was
reached. The data are reported as the photon flux (p/s)
from a 1.6 cm
2 circular region of interest around the
head.
Microscopy analysis
DAB staining of transgene expression in brain sections
was visualized by a Leica DMR optical microscope. In
order to quantify the sensitivity, we determined the ratio
of transduced surface detected by the anti-tag antibody
to the surface detected by the anti-eGFP antibody on
the adjacent slide. Three slides through the transduced
region were quantified per animal with n = 3 per
condition.
Fluorescence staining was visualized by confocal
microscopy using a LSM510 Laser Scanning Microscope
(Zeiss, Zaventem, Belgium). To determine the propor-
tion of transduced cells recognized by the corresponding
antibody, we compared the number of cells recognized
by the anti-tag antibody with the number of eGFP-posi-
tive cells. Counts were based on 12 randomly taken con-
focal images per animal (with n = 3) within the centre
of the transduced region (as in Fig. 4A). Photos were
cropped and adjusted for contrast and brightness with
Adobe Photoshop version 6.0 (Adobe Systems Incorpo-
rated, San Jose, CA, USA).
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